Tagrisso is the only EGFR-targeted medicine approved in Japan for the
treatment of early-stage lung cancer after surgery
Approval based on results from the ADAURA Phase III trial
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
